ERNA ERNEXA THERAPEUTICS INC revenue, earnings and financials
For the quarter ended June 30, 2026, ERNEXA THERAPEUTICS INC reported revenue of n/a, net income of −$4.01M and diluted EPS of −$3.40; for the fiscal year ended December 2025 revenue was n/a.
ERNA annual revenue and earnings
- Fiscal year ended Dec 2025: revenue n/a, gross profit n/a, operating income −$9.32M, net income −$14.1M (margin n/a), EPS −$2.24
- Fiscal year ended Dec 2024: revenue $582K, gross profit $486K, operating income −$15.7M, net income −$44.5M (margin -7652.7%), EPS −$48.96
- Fiscal year ended Dec 2023: revenue $68.0K, gross profit −$168K, operating income −$21.1M, net income −$21.7M (margin -31864.7%), EPS −$4.08
- Fiscal year ended Dec 2022: revenue $0, gross profit $0, operating income −$33.2M, net income −$24.6M (margin n/a), EPS −$8.06
- Fiscal year ended Dec 2021: revenue n/a, gross profit n/a, operating income −$114M, net income −$123M (margin n/a), EPS −$56.61
ERNA quarterly revenue and earnings
- Quarter ended Jun 30, 2026: revenue n/a, net income −$4.01M, EPS −$3.40
- Quarter ended Mar 31, 2026: revenue n/a, net income −$5.51M, EPS −$6.95
- Quarter ended Dec 31, 2025 (from the annual report): revenue n/a, net income −$1.50M, EPS $70.86
- Quarter ended Sep 30, 2025: revenue n/a, net income −$1.24M, EPS −$0.15
- Quarter ended Jun 30, 2025: revenue n/a, net income −$3.14M, EPS −$15.19
- Quarter ended Mar 31, 2025: revenue n/a, net income −$8.20M, EPS −$57.76
- Quarter ended Dec 31, 2024 (from the annual report): revenue $1.00K, net income −$5.76M, EPS $41.31
- Quarter ended Sep 30, 2024: revenue $487K (up 854.9% year over year), net income −$26.6M, EPS −$73.70
- Quarter ended Jun 30, 2024: revenue $47.0K, net income −$5.53M, EPS −$15.34
- Quarter ended Mar 31, 2024: revenue $47.0K, net income −$6.65M, EPS −$1.23
- Quarter ended Dec 31, 2023 (from the annual report): revenue n/a, net income −$6.15M, EPS −$1.14
- Quarter ended Sep 30, 2023: revenue $51.0K, net income −$5.59M, EPS −$1.03
- Quarter ended Jun 30, 2023: revenue n/a, net income −$4.51M, EPS −$0.85
- Quarter ended Mar 31, 2023: revenue $0, net income −$5.42M, EPS −$1.06
- Quarter ended Dec 31, 2022 (from the annual report): revenue n/a, net income −$4.49M, EPS −$0.91
- Quarter ended Sep 30, 2022: revenue $0, net income −$7.32M, EPS −$2.49
- Quarter ended Jun 30, 2022: revenue n/a, net income −$3.40M, EPS −$1.16
- Quarter ended Mar 31, 2022: revenue n/a, net income −$9.38M, EPS −$3.50
- Quarter ended Dec 31, 2021 (from the annual report): revenue n/a, net income −$7.95M, EPS −$21.67
- Quarter ended Sep 30, 2021: revenue n/a, net income −$86.0M, EPS −$34.03
ERNA cash flow, buybacks and dividends
- Fiscal year ended Dec 2025: operating cash flow −$7.02M, share buybacks n/a
- Fiscal year ended Dec 2024: operating cash flow −$15.8M, share buybacks n/a
- Fiscal year ended Dec 2023: operating cash flow −$20.4M, share buybacks n/a
- Fiscal year ended Dec 2022: operating cash flow −$21.0M, share buybacks n/a
- Fiscal year ended Dec 2021: operating cash flow −$23.5M, share buybacks n/a
ERNA balance sheet
- Jun 30, 2026: cash n/a, total assets $6.32M, total liabilities $3.12M, shareholders' equity $3.20M
- Mar 31, 2026: cash n/a, total assets $10.5M, total liabilities $3.68M, shareholders' equity $6.86M
- Dec 31, 2025: cash n/a, total assets $5.83M, total liabilities $3.43M, shareholders' equity $2.40M
- Sep 30, 2025: cash n/a, total assets $6.17M, total liabilities $2.60M, shareholders' equity $3.57M
- Jun 30, 2025: cash $4.32M, total assets $7.58M, total liabilities $3.14M, shareholders' equity $4.44M
- Mar 31, 2025: cash $1.92M, total assets $5.06M, total liabilities $11.0M, shareholders' equity −$5.95M
- Dec 31, 2024: cash $1.73M, total assets $5.27M, total liabilities $3.57M, shareholders' equity $1.70M
- Sep 30, 2024: cash $4.26M, total assets $7.72M, total liabilities $53.1M, shareholders' equity −$45.4M
Is ERNA profitable?
No. ERNEXA THERAPEUTICS INC lost $12.3M over the last four quarters.
What is ERNA's EPS?
Diluted earnings per share over the last four quarters were $60.36; −$3.40 in the latest quarter.